Trials / Completed
CompletedNCT03709134
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Sunnybrook Health Sciences Centre · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.
Detailed description
The study aims to evaluate genetic markers (i.e. CTCs and ctDNA) in breast tumors to predict therapy response and metastatic risk. We aim to investigate genomic markers of treatment response and outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The role of CTCs and ctDNA in predicting response to NAC will also be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Genomic Markers (CTC/ctDNA) | This is a non-interventional study. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2018-10-17
- Last updated
- 2025-01-20
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03709134. Inclusion in this directory is not an endorsement.